Current Diabetes Reports

, Volume 13, Issue 4, pp 509–516 | Cite as

Magnetic Resonance Imaging of the Central Nervous System in Diabetic Neuropathy

  • Iain D. Wilkinson
  • Dinesh Selvarajah
  • Marni Greig
  • Pallai Shillo
  • Elaine Boland
  • Rajiv Gandhi
  • Solomon Tesfaye
Microvascular Complications-Neuropathy (D Ziegler, Section Editor)


Diabetic ‘peripheral’ neuropathy (DPN) is one of the common sequelae to the development of both type-1 and type-2 diabetes mellitus. Neuropathy has a major negative impact on quality of life. Abnormalities in both peripheral vasculature and nerve function are well documented and, in addition, evidence is emerging regarding changes within the central nervous system (CNS) that are concomitant with the presence of DPN. The often-resistant nature of DPN to medical treatment highlights the need to understand the role of the CNS in neuropathic symptomatology and progression, as this may modulate therapeutic approaches. Advanced neuroimaging techniques, especially those that can provide quantitative measures of structure and function, can provide objective markers of CNS status. With that comes great potential for not only furthering our understanding of involvement of the CNS in neuropathic etiology but also most importantly aiding the development of new and more effective, targeted, analgesic interventions.


Diabetic peripheral neuropathy Neuroimaging Magnetic resonance imaging Brain Spine Central nervous system 


Compliance with Ethics Guidelines

Conflict of Interest

Iain D. Wilkinson declares that he has no conflict of interest.

Dinesh Selvarajah declares that he has no conflict of interest.

Marni Greig declares that he has no conflict of interest.

Pallai Shillo declares that he has no conflict of interest.

Elaine Boland declares that she has no conflict of interest.

Rajiv Gandhi declares that he has no conflict of interest.

Solomon Tesfaye declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Tesfaye S. Advances in the management of painful diabetic neuropathy. Curr Opin Support Palliat Care. 2009;3:136–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518–22.PubMedCrossRefGoogle Scholar
  4. 4.
    Gore M, Brandenburg N, Dukes, et al. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptoms Manage. 2005;30:374–85.CrossRefGoogle Scholar
  5. 5.
    Zelman DC, Brandenburg NA, Gore M. Sleep impairment in patients with painful diabetic peripheral neuropathy. Clin J Pain. 2006;22:681–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47(2):123–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Gore M, Brandenburg N, Hoffman DL, et al. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain. 2006;7(12):982–900.Google Scholar
  8. 8.
    Quattrini C, Tesfaye S. Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev. 2003;19:S2–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Jensen T, Baconja MM, Jimenez H, Tesfaye S, Valensi P, Ziegler. Management of diabetic neuropathic pain. Diab Vas Dis Res. 2006;3:108–19.CrossRefGoogle Scholar
  10. 10.
    Tesfaye S, Vileikyte L, Rayman G, et al on behalf of the Toronto Expert Panel on diabetic neuropathy painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011. [Epub ahead of print].Google Scholar
  11. 11.
    Lukic IK, Humpert PM, Nawroth PP, Bierhaus A. The RAGE pathway: activation and perpetuation in the pathogenesis of diabetic neuropathy. Ann N Y Acad Sci. 2008;1126:76–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics. 2009;6:638–47.PubMedCrossRefGoogle Scholar
  13. 13.
    Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7:573–83.PubMedCrossRefGoogle Scholar
  14. 14.
    Said G, Slama G, Selva J. Progressive centripital degeneration of axons in small-fiber type diabetic polyneuropathy. A clinical and pathological study. Brain. 1983;106:791.PubMedCrossRefGoogle Scholar
  15. 15.
    Malik RA, Newrick PG, Sharma AK, et al. Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. Diabetologia. 1989;32:92–102.PubMedCrossRefGoogle Scholar
  16. 16.
    Tesfaye S, Malik R, Ward JD. Vascular factors in diabetic neuropathy. Diabetologia. 1994;37:847–54.PubMedCrossRefGoogle Scholar
  17. 17.
    Malik RA, Tesfaye S, Thompson SD, et al. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia. 1993;36:454–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Malik RA, Tesfaye S, Thompson SD, et al. Transperineurial capillary abnormalities in the sural nerve of patients with diabetic neuropathy. Microvasc Res. 1994;48:236–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Giannini C, Dyck PJ. Ultrastructural morphometric abnormalities of sural nerve endoneurial microvessels in diabetes mellitus. Ann Neurol. 1994;36:408–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Ferguson SC, Blane A, Perros P, McCrimmon RJ, Best JJ, Wardlaw J, et al. Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes. 2003;52:149–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Manschot SM, Brands AM, van der Grond J, et al. Utrecht Diabetic Encephalopathy Study Group. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes. 2006;55:1106–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Reske-Neilsen E, Lundbaek K, Rafaelsen OJ. Pathological changes in the central and peripheral nervous system of young long-term diabetics: II. Spinal cord and peripheral nerve. Diabetologia. 1968;4:34–43.CrossRefGoogle Scholar
  23. 23.
    Slager UT. Diabetic myelopathy. Arch Pathol Lab Med. 1978;102:467–9.PubMedGoogle Scholar
  24. 24.
    Lauterbur PC. Image formation by induced local interactions: examples employing NMR. Nature. 1973;242:190–1.CrossRefGoogle Scholar
  25. 25.
    Wilkinson ID, Paley MNJ. Magnetic resonance imaging: basic principles, Chapter 4. In: Grainger A, Adam D, editors. Diagnostic radiology: a textbook of medical imaging. 5th ed. Churchill Livingstone; 2007. Philadelphia, USA.Google Scholar
  26. 26.
    Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A. 1992;89:5951–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Boguslawska R, Romanowski CAJ, Wilkinson ID, et al. Introduction to functional magnetic resonance imaging. Med Sci Monit. 1999;5:1179–86.Google Scholar
  28. 28.
    Wilkinson ID. Perfusion and diffusion imaging in chronic carotid disease, Chapter 19. In: Gillard, Waldman, Barker, editors. Clinical MR neuroimaging: physiological and functional techniques. Cambridge University Press; Cambridge, UK, 2010.Google Scholar
  29. 29.
    Wilkinson ID, Paley M, Chong WK, et al. Proton spectroscopy in HIV infection: relaxation times of cerebral metabolites. Magn Reson Imaging. 1994;12:951–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Wilkinson ID, Lunn S, Miszkiel KA, et al. Proton MRS and quantitative MRI assessment of the short-term neurological response to anti-retroviral therapy in AIDS. J Neurol Neurosurg Psychiatry. 1997;63:477–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Puts NA, Edden RA. In vivo magnetic resonance spectroscopy of GABA: a methodological review. Prog Nucl Magn Reson Spectrosc. 2012;60:29–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Jones DK, editor. Diffusion MRI: theory, methods, and applications. Oxford University Press; Oxford, UK, 2010. Google Scholar
  33. 33.
    Eaton S, Harris ND, Rajbhandari SM, et al. Spinal cord involvement in diabetic peripheral neuropathy. Lancet. 2001;358:35–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Selvarajah D, Wilkinson ID, Emery CJ, et al. Early involvement of the spinal cord in diabetic peripheral neuropathy. Diabetes Care. 2006;29:2664–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Suzuki C, Ozaki I, Taosaki M, et al. Peripheral and central conduction abnormalities in diabetes mellitus. Neurology. 2000;54:1932–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Wilkinson ID, Selvarajah D, Hutton M, Griffiths PD, Gandhi R, Tesfaye S. Imaging of the cortico-spinal tracts in diabetic neuropathy using diffusion tensor magnetic resonance. Diabetes. 2009;58 (Supp 1): A214.Google Scholar
  37. 37.
    McCormick DA, Bal T. Sensory gating mechanisms of the thalamus. Curr Opin Neurobiol. 1994;4:550–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Selvarajah D, Wilkinson ID, Emery CJ, Shaw PJ, Griffiths PD, Gandhi R, et al. Thalamic neuronal dysfunction and chronic sensorimotor distal symmetrical polyneuropathy in patients with type 1 diabetes mellitus. Diabetologia. 2008;51:2088–92.PubMedCrossRefGoogle Scholar
  39. 39.
    Gandhi R, Selvarajah D, Emery CJ, Wilkinson ID, Tesfaye S. Neurochemical abnormalities within sensory pathways in the brain in diabetic neuropathy. Diabetologia. 2008;51(Supp 1):1–588.Google Scholar
  40. 40.
    Sorensen L, Siddall PJ, Trenell MI, Yue DK. Differences in metabolites in pain-processing brain regions in patients with diabetes and painful neuropathy. Diabetes Care. 2008;31:980–1.PubMedCrossRefGoogle Scholar
  41. 41.
    Petrou M, Pop-Busui R, Foerster BR, Edden RA, et al. Altered excitation-inhibition balance in the brain of patients with diabetic neuropathy. Acad Radiol. 2012;19:607–12.PubMedCrossRefGoogle Scholar
  42. 42.
    •• Selvarajah D, Wilkinson ID, Gandhi R, Griffiths PD, Tesfaye S. Microvascular perfusion abnormalities of the thalamus in painful but not painless diabetic polyneuropathy: a clue to the pathogenesis of pain in type 1 diabetes. Diabetes Care. 2011;34:718–20. Data from this preliminary study implies increased blood supply to the thalamus in patients with painful diabetic neuropathy.PubMedCrossRefGoogle Scholar
  43. 43.
    Paulson PE, Wiley JW, Morrow TJ. Concurrent activation of the somatosensory forebrain and deactivation of periacqueductal gray associated with diabetes-induced neuropathic pain. Exp Neurol. 2007;208:305–13.PubMedCrossRefGoogle Scholar
  44. 44.
    Fischer TZ, Tan AM, Waxman SG. Thalamic neuron hyperexcitability and enlarged receptive fields in the STZ model of diabetic pain. Brain Res. 2009;1268:154–61.PubMedCrossRefGoogle Scholar
  45. 45.
    Melzack R. From the gate to the neuromatrix. Pain. 1999;(Suppl 6):S121–6.Google Scholar
  46. 46.
    Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain. 2005;9:463–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Bushnell MC, Duncan GH, Hofbauer RK, et al. Pain perception: is there a role for primary somatosensory cortex? Proc Natl Acad Sci U S A. 1999;96:7705–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Kanda M, Nagamine T, Ikeda A, et al. Primary somatosensory cortex is actively involved in pain processing in human. Brain Res. 2000;853:282–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Peyron R, García-Larrea L, Grégoire MC, et al. Parietal and cingulate processes in central pain. A combined positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) study of an unusual case. Pain. 2000;84:77–87.PubMedCrossRefGoogle Scholar
  50. 50.
    Wilkinson ID, Gandhi RA, Hunter MD, et al. Functional MRI and response to pain in diabetic neuropathy. Diabet Med. 2007;24 Suppl 1:187.Google Scholar
  51. 51.
    Wilkinson ID, Gandhi R, Hunter MD, et al. A functional magnetic resonance imaging study demonstrating alterations in brain responses to acute pain stimulation in diabetic neuropathy. Diabetologia. 2007;50(Supp 1):1–538.Google Scholar
  52. 52.
    Tseng MT, Chiang MC, Chao CC, Tseng WY, Hsieh, ST. fMRI evidence of degeneration-induced neuropathic pain in diabetes: enhanced limbic and striatal activations. Hum Brain Mapp. 2012. [Epub ahead of print].Google Scholar
  53. 53.
    • Manor B, Newton E, Abduljalil A, Novak V. The relationship between brain volume and walking outcomes in older adults with and without diabetic peripheral neuropathy. Diabetes Care. 2012;35:1907–12. In this study, patients’ walking disability is linked with the presence of intracranial brain atrophy.PubMedCrossRefGoogle Scholar
  54. 54.
    •• Selvarajah D, Maxwell M, Davies J, et al. Diabetic neuropathy associated with increased cortical atrophy on brain MRI in patients with Type-1 Diabetes. Diabetic Med. 2013;30 Suppl 1:14. This work identifies atrophy of the somatosensory cortex in people with diabetic neuropathy.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Iain D. Wilkinson
    • 1
  • Dinesh Selvarajah
    • 2
  • Marni Greig
    • 1
    • 3
  • Pallai Shillo
    • 1
    • 2
    • 3
  • Elaine Boland
    • 1
  • Rajiv Gandhi
    • 3
  • Solomon Tesfaye
    • 3
  1. 1.Academic RadiologyUniversity of SheffieldSheffieldUK
  2. 2.Academic Diabetes, Endocrinology & MetabolismUniversity of SheffieldSheffieldUK
  3. 3.Diabetes ResearchRoyal Hallamshire HospitalSheffieldUK

Personalised recommendations